Infliximab Does Not Lead to Reduction in the Interferon-gamma and Lymphoproliferative Responses of Patients with Moderate to Severe Psoriasis

Files in this item

This item appears in the following Collection(s)

Search DSpace



Browse

My Account

Statistics